Lilly (LLY) gets a CRL for the eczema candidate, lebrikizumab, based on inspection findings at a third-party manufacturer.
Lilly has been bolstering its pipeline through small deals as its cancer therapy Alimta faces fierce competition from copycat versions while betting on potential blockbuster drug tirzepatide, or Mounjaro, to drive growth. Point Biopharma is currently testing radioligand therapy candidates, PNT2002 and PNT2003, in late-stage studies. The experimental therapies combine radioactive particles that kill cells with molecules that attach themselves to the tumors.
ACM Research and Advance Auto Parts have been highlighted as Zacks Bull and Bear of the Day.